'Fourfold Increase in PhD-Level Talent'... DXVX "Will Achieve Success in Exporting mRNA Platform Technology"

Bio healthcare specialist company DXVX declared, "We have completed the establishment of PhD-level professional personnel and the reorganization of the research team," and promised, "We will show results of mRNA platform technology export within this year."

On the 17th, DXVX announced, "This month, we completed the reorganization of the R&D team consisting of about 40 master's and PhD-level professionals." Among them, 16 are PhD holders and 28 are master's degree holders, which is a fourfold increase in PhD-level personnel and nearly threefold increase in master's-level personnel compared to 2023.

The R&D team was formed with four teams led by Park Sang-jin, Executive Director and a top authority in molecular genetics. Each team includes Dr. Lee Kyu-hang, an expert in non-clinical research; Dr. Lee Kyung-ik, a specialist in organic synthesis; Dr. Lim Chang-gi, a peptide expert; and Dr. Baek Sang-hoon, a cell culture specialist.

DXVX explained that most members are recognized authorities who have proven their capabilities at companies such as Hanmi Pharmaceutical and Green Cross.

Additionally, Vice President Shim Sung-nyeo, who has experience at global pharmaceutical companies such as Merck, GSK, and Teva, was appointed as head of DXVX’s product development division and is expected to lead clinical approvals. Financial expert Executive Director Yoon Myung-jin, who handled business development at LG Chem and PwC, was appointed head of the R&DB division to oversee business development of research outputs and global market expansion.

CEO Kwon Kyu-chan, who joined in August 2023, is a global new drug development expert with over 30 years of experience at LG Chem, Daewoong Pharmaceutical, and Hanmi Pharmaceutical. He has led three US FDA approvals, more than 20 European Medicines Agency approvals, and over 100 overseas approvals, and has achieved overseas sales exceeding 200 billion KRW.

DXVX stated, "Since CEO Kwon’s appointment in 2023, we have recruited about 40 experts and reorganized the team within a year and a half," adding, "We will show results in new drug development as well as mRNA platform technology exports going forward."

In fact, DXVX is developing various new drugs including infectious disease and cancer vaccines, metabolic disease treatments for obesity and diabetes, antiviral agents, and ophthalmic disease treatments. The company also possesses the world’s only mRNA ultra-long-term storage and mass production platform, as well as a universal NGS (next-generation sequencing) platform.

At the JP Morgan Healthcare Conference held earlier this month, investors and pharmaceutical companies showed strong interest in DXVX’s new drug pipeline and mRNA platform, and it is reported that DXVX signed confidentiality agreements and material transfer agreements with multiple companies.

CEO Kwon Kyu-chan of DXVX emphasized, "We expect to complete technology export achievements within this year," and added, "In particular, we will make the mRNA platform a global standard."